BridgeMD
Weight-loss Effects aNd absorption of Direct oral anticoagulants in roux-en-Y gastric bypass patients: a prospective study (WENDY)
EU CTIS ID: 2024-519737-30-00
What this study is testing
To assess the difference in the pharmacokinetics of apixaban before and after RYGB
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients who are screened and approved to undergo laparoscopic ggastric bypass
- Age 18 years or older
You likely can't join if
- Symptomatic thrombos at inclusion
- Use of antiplatelet agent or chronic use of NSAID
- Known allergy to apixaban
- Inadequate or lack of contraceptive methods by the patient when relevant
- Inability to adhere to treatment or to the follow-up visits
- Current use of anticoagulant medication, such as apixaban, rivaroxaban, edoxaban, dabigatran, acenocoumarol, fenprocoumon, low molecular weighted heparin or heparin
See the full eligibility criteria
- Patients who are screened and approved to undergo laparoscopic ggastric bypass
- Age 18 years or older
- Symptomatic thrombos at inclusion
- Use of antiplatelet agent or chronic use of NSAID
- Known allergy to apixaban
- Inadequate or lack of contraceptive methods by the patient when relevant
- Inability to adhere to treatment or to the follow-up visits
- Current use of anticoagulant medication, such as apixaban, rivaroxaban, edoxaban, dabigatran, acenocoumarol, fenprocoumon, low molecular weighted heparin or heparin
- Major bleeding defined according to the International Society on Thrombosis and Haemostasis in the 6 months prior to start participation
- Liver cirrhosis
- Severe renal insufficiency (eGFR <30 ml/min/1.73 m2)
- Concurrent use of strong inhibitors or inducers of cytochrome P450 or P-glycoprotein
- Medical or psychological condition that would not permit completion of the study or signing of informed consent, including life expectancy less than six months, or unwillingness to sign informed consent
- Known bleeding diathesis or bleeding disorder
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.